Pfizer Investor Presentation — January 2020

Document content

Earnings Teleconference

Senior Vice President, Investor Relations 3Forward -Looking Statements and Non- GAAP Financial Information

Our discussions during this conference call will include forward -looking statements about, among other things, our anticipated future operating and

financial performance, expectations for our product pipeline, in -line products and product candidates, including anticipated regulatory submissions,

data read -outs, study starts, approvals, revenue contribution, growth, performance, timing of exclusivity and potential benefits , strategic reviews,

capital allocation objectives, the benefits anticipated from the reorganization of our commercial operations in 2019, plans f or and prospects of our

acquisitions and other business development activities, including our proposed transaction with Mylan N.V. (Mylan) to combine Upjohn and Mylan

to create a new global pharmaceutical company, our acquisition of Array BioPharma Inc. and our transaction with GlaxoSmithKline plc which

combined our respective consumer healthcare businesses into a new consumer healthcare joint venture, our ability to successfu llycapitalize on

growth opportunities and prospects, manufacturing and product supply and plans relating to share repurchases and dividends that are subject to

substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by s uchstatements.

Additional information regarding these factors can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended Dec ember 31, 2018

and in our subsequent reports on Form 10 -Q, including in the sections thereof captioned “Risk Factors” and “Forward -Looking Info rmation and

Factors That May Affect Future Results”, as well as in our subsequent reports on Form 8 -K, all of which are filed with the U.S. Securities and